Because no information is available on the use of terazosin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information in nursing mothers was not found as of the revision date. However, the pharmacologically similar drug prazosin does not affect serum prolactin concentration in patients with hypertension.[1,2] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
References
1.
Barbieri C, Caldara R, Ferrari C, et al. Metabolic effects of prazosin. Clin Pharmacol Ther. 1980;27:313–6. [PubMed: 6102000]
2.
Barbieri C, Ferrari C, Borzio M, et al. Metabolic effects of chronic prazosin treatment. Horm Metab Res. 1980;12:331–4. [PubMed: 6105121]
Substance Identification
Substance Name
Terazosin
CAS Registry Number
63590-64-7
Drug Class
Breast Feeding
Lactation
Adrenergic alpha-Antagonists
Antihypertensive Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
